Home › Funds › Orland Properties Ltd › LYEL

Orland Properties Ltd position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

Orland Properties Ltd reported holding 754,698 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$7.4M, representing 4.97% of its reported portfolio and ranking #3 among its reported holdings. Orland Properties Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)754.70K sh
Reported value held$7.39M
Portfolio Weight4.97%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Orland Properties Ltd's LYEL position evolved

Orland Properties Ltd first disclosed a stake in LYEL in Q3 2023 at 15,093,969 shares (US$22.2M). The position peaked in Q1 2024 at 15,093,969 shares, worth US$33.7M. Across 13 filings, Orland Properties Ltd increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 754,698 shares valued at US$7.4M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 15.09M $22.19M New
Q4 2023 15.09M $29.28M Hold
Q1 2024 15.09M $33.66M Hold
Q2 2024 15.09M $21.89M Hold
Q3 2024 15.09M $20.83M Hold
Q4 2024 15.09M $9.66M Hold
Q1 2025 15.09M $8.15M Hold
Q2 2025 754.70K $6.67M Reduce
Q3 2025 754.70K $12.26M Hold
Q4 2025 754.70K $23.23M Hold
Q1 2026 754.70K $15.14M Hold
Q2 2026 754.70K $10.60M Hold
Q3 2026 754.70K $7.39M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 28 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Decheng Capital LLC (US$9.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has Orland Properties Ltd held LYEL?

Orland Properties Ltd has disclosed LYEL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Orland Properties Ltd's current position in LYEL?

As of Q3 2026, Orland Properties Ltd holds 754.70K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $7.39M, representing 4.97% of its reported portfolio and ranking #3.

Has Orland Properties Ltd been buying or selling LYEL?

In the latest 13F filing (Q3 2026), Orland Properties Ltd held unchanged its position in LYEL. The position peaked in Q1 2024 at 15.09M shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Decheng Capital LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.